Multiple Myeloma News & Features
Patients with multiple myeloma may be vulnerable to financial toxicity, even those with health insurance and those who make more than $100,000 a year, due to the higher use of novel therapeutics and extended duration of myeloma treatment.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance.
Among patients with multiple myeloma, high compliance with exercise was associated with improvements in fatigue.
A genetic variation in the FOPNL gene can increase mortality for patients with multiple myeloma.
Multiple Myeloma Clinical Trials
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
- New Approach Tackles Hormone Therapy Resistance in Breast Cancer
- Patients With Multiple Myeloma Vulnerable to Financial Toxicity Due to Costly Treatments
- Engineered Switch in Immune Cell Technology Makes Therapy More Precise, and Safer
- Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk
- Laparascopic Surgery Does Not Improve Outcomes Over Open Resection for Rectal Cancer
- Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
- Smokers and Nonsmokers Who Develop NSCLC Display Differences
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|